

## DAFTAR PUSTAKA

- 1 Nobile CJ, Johnson AD. *Candida albicans* Biofilms and Human Disease. *Annu Rev Microbiol* 2015; **69**: 71–92.
- 2 Suyoso S. *Penatalaksanaan Dermatomikosis Superfisialis Masa Kini*. 1st ed. Universitas Airlangga: Surabaya, 2002.
- 3 Prevention C for DC and, (NCEZID) NC for E and ZID, Division of Foodborne W and ED (DFWED). *Candida* infections of the mouth, throat, and esophagus. CDC. .
- 4 Dangi Y, Soni M, Namdeo K. Oral candidiasis: A review. *Int J Pharm Pharm Sci*. 2010; : 2:36-41.
- 5 Moran GP, Coleman DC, Sullivan DJ. *Candida albicans* versus *Candida dubliniensis*: Why Is *C. albicans* More Pathogenic? 2011.
- 6 Nur'aeny N, Hidayat W, Dewi T, Herawati E, Wahyuni I. Profil oral candidiasis di bagian ilmu penyakit mulut RSHS Bandung periode 2010-2014. *Maj Kedokt Gigi Indones* 2017; : 23–28.
- 7 Vecchiarelli A, Pericolini E, Gabrielli E, Pietrella D. New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges. *Front Microbiol* 2012; **3**: 294.
- 8 Oliveira DA, Salvador AA, Smânia A, Smânia EFA, Maraschin M, Ferreira SRS. Antimicrobial activity and composition profile of grape (*Vitis vinifera*) pomace extracts obtained by supercritical fluids. *J Biotechnol* 2013; **164**: 423–432.
- 9 Filocamo A, Bisignano C, Mandalari G, Navarra M. In Vitro Antimicrobial Activity and Effect on Biofilm Production of a White Grape Juice (*Vitis vinifera*) Extract. *Hindawi* 2015; : 5.
- 10 Suryaningsih A, Chimaeroh S, Benyamin B. Uji Efektivitas Anggur Merah (*Vitis Vinivera*) Terhadap Pertumbuhan *Candida Albicans* Secara In Vitro. *Medali J Media Intelekt*; **2**: 5–8.
- 11 Cortell JM, Kennedy JA. Effect of Shading on Accumulation of Flavonoid

- Compounds in (*Vitis vinifera* L.) Pinot Noir Fruit and Extraction in a Model System. *Dep Food Sci Technol Oregon State Univ* 2006; **54**.
- 12 Li H, Wang X, Li P, Li Y, Wang H. Comparative study of antioxidant activity of grape (*Vitis vinifera*) seed powder assessed by different methods. *J Food Drug Anal* 2008; **16**: 67–73.
  - 13 Fluconazole. Drugbank. 2005. <https://www.drugbank.ca/drugs/DB00196#reference-A178774> (accessed 22 Nov2019).
  - 14 Levinson W. *Medical Microbiology Pathogenesis and Immunology; Examination & Board Review*. 8th ed. Mcgrow-Hill Companies: United States of America, 2004.
  - 15 Mclane B., Timothy A. *Microbial Pathogenesis; A Principles-Oriented Approach*. First Edit. Blackwell Science Inc: United States of America, 1999.
  - 16 ITIS. *Candida albicans*. Smithson. Inst. 1996. [https://www.itis.gov/servlet/SingleRpt/SingleRpt?search\\_topic=TSN&search\\_value=194598#null](https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=194598#null) (accessed 1 May2020).
  - 17 Mutiawati VK. Pemeriksaan Mikrobiologi Pada *Candida albicans*. *J Kedokt Syiah Kuala* 2015; **15**. <http://www.jurnal.unsyiah.ac.id/JKS/article/viewFile/5013/4444>.
  - 18 Vandepitte J, Verhaegen J, Engbaek K, Rohner P. Basic Laboratory Procedures in Clinical Bacteriology. *World Heal Organ* 2003; **2**: 144–150.
  - 19 Greenwood D, Slack R, Peutherer J. *Medical Microbiology A Guide to Microbial Infection: Pathonesis, Immunity, Laboratory Diagnosis and Control*. *Churchill Livingstone Elsevier* 2007; **60**: 602-4,614-16.
  - 20 *Candida* species. Mycoses Study Gr. Educ. Res. Consort. 1923.<https://drfungus.org/knowledge-base/candida-species/> (accessed 14 Jul2020).
  - 21 Walsh TJ, Hayden RT, Larone D. *Medical Important Fungi A Guide to Identification*. New York.
  - 22 Hidalgo J, Jose A. Candidiasis. Medscape. 2010. <https://emedicine>.

- medscape.com/article/213853-overview#a0199 (accessed 15 Jul2020).
- 23 Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. *Virulence* 2013; **4**: 119–128.
  - 24 Kuleta J., Maria R., Andrzej K. Fungi Pathogenic To Humans: Molecular Bases of Virulence of Candida Albicans, Cryptococcus Neoformans and Aspergillus Fumigates. *Act Biochim Pol* 2009; : 211–224.
  - 25 Chaffin W., Lopez-Ribot J., Casanova M, Gozalbo D, Martinez J. Cell Wall and Secreted Proteins of Candida Albicans: Identification, Function, and Expression. *Microbiol Mol Biol Rev* 1998; : 130–180.
  - 26 Naglik JR, Richardson JP, Moyes DL. Candida albicans Pathogenicity and Epithelial Immunity. *PLoS Pathog* 2014; **10**: 8–11.
  - 27 Agrawal A, Singh A, Verma R, Murari A. Oral candidiasis: An overview. *J Oral Maxillofac Pathol* 2014; **18**: 81.
  - 28 Pathak A, Jain N, Joshi R. Antibiogram of candida species isolated from mono and multi-species oral candidal carriage using disk diffusion method. *Saudi J Heal Sci* 2012; **1**: 132.
  - 29 Prevention C for DC and, (NCEZID) NC for E and ZID, Division of Foodborne W and ED (DFWED). Candidiasis. CDC. 2020. <https://www.cdc.gov/fungal/diseases/candidiasis/index.html>.
  - 30 Tewu Walangare, Taufiq Hidayat SB. Profil Spesies Candida pada Pasien Kandidiasis Oral dengan Infeksi HIV & AIDS. *Berk Ilmu Kesehatan Kulit dan Kelamin* 2014; **26**: 29–35.
  - 31 Parkarwar C, Qadri S, Zianuddin S, Zaidi N, Kale L, Pansambal V *et al*. Oral Candidiasis- A Review Oral Candidiasis- A Review. *Webmed Cent Dent* 2017; **6**: 975–985.
  - 32 Naglik JR, Challacombe SJ, Hube B. Treatment of oropharyngeal and esophageal candidiasis. *Microbiol Mol Biol Rev* 2003; **67**: 400–28.
  - 33 Klajn-Laslo M. Chronic candidiasis - pathogenesis, symptoms, diagnosis and treatment. *Zb Matice Srp za Prir Nauk* 2009; : 267–274.
  - 34 Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal Biofilms and Drug

- Resistance. *Emerg Infect Dis* 2004; **10**: 14–19.
- 35 Nelwan E, Wisaksana R. Clinical manifestation of oral Candidiasis in a HIV patient. 2010; **42**.
- 36 Spampinato C, Leonardi D. Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents. NCBI. 2013. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708393/> (accessed 19 Oct2020).
- 37 Maertens JA. History of the development of azole derivatives. *Clin Microbiol Infect* 2004; **10**: 1–10.
- 38 Alsaad AMS, Kaplan YC, Koren G. Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis. *Reprod Toxicol* 2015; **52**: 78–82.
- 39 McGraw-Hill Education. *Basic and Clinical Pharmacology*. 13th ed. New York, 2015.
- 40 Amichai B, Grunwald M. Adverse Drug Reactions of the New Oral Antifungal Agents-Terbinafine, Fluconazole, and Itraconazole. *Int J Dermatol* 1998; **37**: 410–5.
- 41 Pappas P, Kauffman C, Johnson P. Alopecia associated with fluconazole therapy. *Intern Med* 1995; **123**: 354–7.
- 42 Bioresource C of A and. Grape. Univ. Saskatchewan. <https://gardening.usask.ca/articles-growing-information/grapes.php>.
- 43 cancer chemoprevention research center. Anggur (Vitis vinifera). UGM Farm. [https://ccrc.farmasi.ugm.ac.id/?page\\_id=2401](https://ccrc.farmasi.ugm.ac.id/?page_id=2401) (accessed 29 Sep2020).
- 44 USDA. Grapes, red or green (European type, such as Thompson seedless), raw. Agric. Res. Serv. 2019.<https://fdc.nal.usda.gov/fdc-app.html#/food-details/174683/nutrients>.
- 45 Suwanto A. *9 Buah & Sayur Sakti Tangkal Penyakit*. Liberplus: Yogyakarta, 2010.
- 46 Chair WFB, Donald V B, Hill RA. Vitis vinifera (Grape) Ingredients as Used in Cosmetics. *Sci Lit Rev* 2012.

- 47 En-qin X, Gui F, Hua B. Biological Activities of Polyphenols from Grapes. *Int J Mol Sci* 2010.
- 48 Gonzalez Ureña A, Orea JM, Montero C, Jiménez JB, González JL, Sánchez A *et al.* Improving postharvest resistance in fruits by external application of trans-resveratrol. *J Agric Food Chem* 2003; **51**: 82–89.
- 49 Sitheeque MAM, Panagoda GJ, Yau J, Amarakoon AMT, Udagama URN, Samaranayake LP. Antifungal activity of black tea polyphenols (catechins and theaflavins) against candida species. *Chemotherapy* 2009; **55**: 189–196.
- 50 Wang C, Cheng H, Guan Y. In Vitro Activity of Garlic Acid Against Candida Albicans Biofilm. *NCBI* 2009; **39**.
- 51 Aboody MS Al, Mickymaray S. Anti-fungal efficacy and mechanisms of flavonoids. *Antibiotics* 2020; **9**. doi:10.3390/antibiotics9020045.
- 52 Salehi B, Mishra A, Nigam M, Sener B, Kilic M, Sharifi-Rad M *et al.* Resveratrol: A Double-Edged Sword in Health Benefits. *Biomedicines* 2018; **6**: 91.
- 53 Fan X, Mattheis JP. Inhibition of oxidative and antioxidative enzymes by trans-resveratrol. *J Food Sci* 2001; **66**: 200–203.
- 54 Tsitsigiannis DI, Kowieski TM, Zarnowski R, Keller NP. Three putative oxylipin biosynthetic genes integrate sexual and asexual development in *Aspergillus nidulans*. *Microbiology* 2005; **151**: 1809–1821.
- 55 Navarro-Martinez MD. Tea polyphenol epigallocatechin-3-gallate inhibits ergosterol synthesis by disturbing folic acid metabolism in *Candida albicans*. *J Antimicrob Chemother* 2006; **57**: 1083–1092.
- 56 Rosas EC, Correa LB, das Graças Henriques M. Antiinflammatory Properties of *Schinus terebinthifolius* and Its Use in Arthritic Conditions. In: *Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases*. Elsevier, 2019, pp 489–505.
- 57 Kim K-J, Sung WS, Suh BK, Moon S-K, Choi J-S, Kim JG *et al.* Antifungal activity and mode of action of silver nano-particles on *Candida albicans*. *BioMetals* 2009; **22**: 235–242.

- 58 Lim S., Darah I, Jain K. Antimicrobial activities of tannins extracted from *Rhizophora apiculata* Barks. *J Trop For Sci* 2006; **18**: 59–65.
- 59 Schaefer HM, Rentzsch M, Breuer M. Anthocyanins Reduce Fungal Growth in Fruits. *Nat Prod Commun* 2008; **3**: 1934578X0800300.
- 60 Varghese N, Joy P. Microbiology Laboratory Manual. 2016. [https://www.researchgate.net/publication/306018042\\_Microbiology\\_Laboratory\\_Manual](https://www.researchgate.net/publication/306018042_Microbiology_Laboratory_Manual) (accessed 10 Nov 2019).
- 61 Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial disk susceptibility tests: Approved standard - Eleventh edition*. 2012.
- 62 Cihlar RL, Calderone RA. *Candida albicans: Methods and Protocols: Preface*. Humana Press: Totowa, NJ, 2009 <http://link.springer.com/10.1007/978-1-60327-151-6>.
- 63 Schutze GE, Etzel J V., Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. *N Engl J Med* 1994; **330**: 1759–1760.

